中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2013年
4期
397-399
,共3页
药物化疗,联合%透热疗法%白细胞介素-2%腹水
藥物化療,聯閤%透熱療法%白細胞介素-2%腹水
약물화료,연합%투열요법%백세포개소-2%복수
Drug therapy,combination%Diathermy%Interleukin-2%Ascites
目的 探讨腹腔热灌注化疗联合白介素-2治疗中老年人恶性腹水的疗效及不良反应.方法 将入选恶性腹水患者47例随机分为实验组和对照组,实验组腹腔置引流管引流后灌注紫衫醇脂质体、顺铂、白介素-2、地塞米松,嘱患者变换体位,即刻给予高能聚焦超声刀腹腔灌注液热疗,焦区温度控制在42 C～43 C之间,维持90 min以上；对照组腹腔置引流管引流后腹腔内灌注紫衫醇脂质体、顺铂、白介素-2、地塞米松,嘱患者变换体位,不进行热疗. 结果 近期缓解率实验组为75.0％,对照组为43.5％,实验组明显高于对照组(x2=4.85,P＜0.05)；实验组患者中位生存时间为34周,对照组为21周,差异有统计学意义(x2=7.96,P＜0.05)；两组不良反应发生情况比较,差异无统计学意义(P＞0.05). 结论 腹腔热灌注化疗联合白介素-2治疗晚期肿瘤恶性腹水的近期缓解率明显优于腹腔灌注化疗联合白介素-2,热灌注化疗能显著延长患者的中位生存期,不良反应无明显增加,值得临床推广应用.
目的 探討腹腔熱灌註化療聯閤白介素-2治療中老年人噁性腹水的療效及不良反應.方法 將入選噁性腹水患者47例隨機分為實驗組和對照組,實驗組腹腔置引流管引流後灌註紫衫醇脂質體、順鉑、白介素-2、地塞米鬆,囑患者變換體位,即刻給予高能聚焦超聲刀腹腔灌註液熱療,焦區溫度控製在42 C～43 C之間,維持90 min以上；對照組腹腔置引流管引流後腹腔內灌註紫衫醇脂質體、順鉑、白介素-2、地塞米鬆,囑患者變換體位,不進行熱療. 結果 近期緩解率實驗組為75.0％,對照組為43.5％,實驗組明顯高于對照組(x2=4.85,P＜0.05)；實驗組患者中位生存時間為34週,對照組為21週,差異有統計學意義(x2=7.96,P＜0.05)；兩組不良反應髮生情況比較,差異無統計學意義(P＞0.05). 結論 腹腔熱灌註化療聯閤白介素-2治療晚期腫瘤噁性腹水的近期緩解率明顯優于腹腔灌註化療聯閤白介素-2,熱灌註化療能顯著延長患者的中位生存期,不良反應無明顯增加,值得臨床推廣應用.
목적 탐토복강열관주화료연합백개소-2치료중노년인악성복수적료효급불량반응.방법 장입선악성복수환자47례수궤분위실험조화대조조,실험조복강치인류관인류후관주자삼순지질체、순박、백개소-2、지새미송,촉환자변환체위,즉각급여고능취초초성도복강관주액열료,초구온도공제재42 C～43 C지간,유지90 min이상；대조조복강치인류관인류후복강내관주자삼순지질체、순박、백개소-2、지새미송,촉환자변환체위,불진행열료. 결과 근기완해솔실험조위75.0％,대조조위43.5％,실험조명현고우대조조(x2=4.85,P＜0.05)；실험조환자중위생존시간위34주,대조조위21주,차이유통계학의의(x2=7.96,P＜0.05)；량조불량반응발생정황비교,차이무통계학의의(P＞0.05). 결론 복강열관주화료연합백개소-2치료만기종류악성복수적근기완해솔명현우우복강관주화료연합백개소-2,열관주화료능현저연장환자적중위생존기,불량반응무명현증가,치득림상추엄응용.
Objective To evaluate the efficacy of intraperitoneal hyperthcrmic chemoperfusion in combination with interleukin 2 in the treatment of malignant ascites.Methods A total of 47 patients aged 47-75 years with malignant ascites were randomly divided into two groups:the experimental group and the control group.All patients received a closed drainage and were treated with paclitaxel liposome,cisplatin (DDP),interleukin-2 and dexamethasone by intraperitonealinfusion.Patients were asked to change the body position.In addition,the patients in experimental group were received the high frequency hyperthermia immediately at a temperature of 42℃ to 43℃ for 90 minutes.Results The remission rate (RR) was higher in the experimental group than in the control group (75.0 ％ vs.43.5％,x2 =4.85,P＜0.05).The median survival time (MST) was longer in the experimental group than in the control group (34 weeks vs.21 weeks,P＜0.05).There were no significant differences in adverse reaction incidences between groups (P ＞ 0.05).Conclusions Compared with intraperitoneal chemoperfusion alone,the intraperitoneal hyperthermic chemoperfusion has a higher RR and longer MST with no increased adverse reaction incidence,which can be in the clinical application.
